184 related articles for article (PubMed ID: 2311067)
1. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
Steinberg WM; Gelfand R; Anderson KK; Glenn J; Kurtzman SH; Sindelar WF; Toskes PP
Gastroenterology; 1986 Feb; 90(2):343-9. PubMed ID: 2416628
[TBL] [Abstract][Full Text] [Related]
4. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
5. Determination of tumor marker levels in cystic fluid of benign liver cysts.
Iwase K; Takenaka H; Oshima S; Yagura A; Nishimura Y; Yoshidome K; Tanaka T
Dig Dis Sci; 1992 Nov; 37(11):1648-54. PubMed ID: 1385056
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
7. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues.
Kitagawa Y; Iwai M; Muramatsu A; Tanaka S; Mori T; Harada Y; Okanoue T; Kashima K
Histopathology; 2002 May; 40(5):472-9. PubMed ID: 12010368
[TBL] [Abstract][Full Text] [Related]
9. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis.
Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R
Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255
[TBL] [Abstract][Full Text] [Related]
11. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
12. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
Changchine CS; Yung CY; Tzen KY
Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
[TBL] [Abstract][Full Text] [Related]
13. [Fundamental and clinical evaluation of IRMA for serum SPan-1 antigen].
Fukuda Y; Murakami M; Fukuchi M
Kaku Igaku; 1990 Apr; 27(4):405-13. PubMed ID: 2165543
[No Abstract] [Full Text] [Related]
14. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
[TBL] [Abstract][Full Text] [Related]
15. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
16. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.
Benini L; Cavallini G; Zordan D; Rizzotti P; Rigo L; Brocco G; Perobelli L; Zanchetta M; Pederzoli P; Scuro LA
Pancreas; 1988; 3(1):61-6. PubMed ID: 3163149
[TBL] [Abstract][Full Text] [Related]
17. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
18. Expression of CA19-9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins.
Ho JJ; Norton K; Chung YS; Kim YS
Oncol Res; 1993; 5(9):347-56. PubMed ID: 7518709
[TBL] [Abstract][Full Text] [Related]
19. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]